July 8, 2020 by Chain Drug Review
Carol Lynch, Civica Rx, generic drugs, Martin VanTrieste, Sandoz
Pharmacy, Supplier News
PRINCETON, N.J. — Sandoz has entered into a long-term agreement with Civica Rx to manufacture and supply critical injectable generic medicines, to help reduce supply shortages and ensure acute care settings can deliver optimal patient care. Under the five-year agreement, Sandoz will supply six injectable medicines widely used at Civica’s 1,200 U.S. member hospitals, to
August 13, 2019 by Dane Pearson and Brian Moy
generic drugs, pharmacists
August 12, 2019, Opinion
Perhaps the best way to begin the complicated story of generic drugs, and how using a data-based approach could help pharmacists, is to tell a bit about the rise of generics. How did we reach a point where many branded drugs are actually cheaper than generics for holders of Medicare Part D? First, it should
June 27, 2017 by Chain Drug Review
drug prices, FDA, generic drugs, new generic drugs
Leading Headlines, Pharmacy
WASHINGTON — The Food and Drug Administration today announced two new steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives. The agency published a list of off-patent, off-exclusivity branded drugs without approved generics, and also implemented, for the first time, a new policy to expedite the review of
June 12, 2017 by Geoff Walden and Chain Drug Review
2017 AAM Generic Drug Access & Savings in the U.S., AAM, Association for Accessible Medicines, Chip Davis, generic drugs, Prescription abandonment
Featured Articles, Leading Headlines, Pharmacy, Supplier News
WASHINGTON — Prescription abandonment is sharply higher for branded drugs than generic drugs, a new annual report commissioned by the Association for Accessible Medicines (AAM) found. AAM said Monday that abandonment — defined as the failure to pick up a new script — was nearly three times as high for brand-name drugs as for generics
February 14, 2017 by Chain Drug Review
AAM, Apotex, Association for Accessible Medicines, biosimilars, Chip Davis, generic drugs, Generic Pharmaceutical Association, GPhA, GPhA Annual Meeting, Heather Bresch, Jeff Watson, Lupin Pharmaceuticals, mylan, Paul McGarty, Peter Goldschmidt, Sandoz
Featured Articles, Leading Headlines, Pharmacy, Supplier News
WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly
October 19, 2016 by Chain Drug Review
Chip Davis, generic drugs, Generic Pharmaceutical Association, generic prescription drugs, GPhA, GPhA's 2016 Generic Drug Savings and Access in the United States report, health care spending, QuintilesIMS Institute, U.S. drug spending
Leading Headlines, Pharmacy, Retail News
WASHINGTON — Annual health care savings from generic prescription drugs rose nearly 10% last year to $227 billion, according to the Generic Pharmaceutical Association (GPhA). GPhA’s 2016 Generic Drug Savings and Access in the United States report, released Wednesday, tallied the 10-year national savings for generics at $1.46 trillion, representing a gain of 328% from
September 26, 2016 by Greg Jacobson and Chain Drug Review
2016 presidential election, Affordable Care Act, Donald Trump, drug pricing, generic drugs, health care, Hillary Clinton, prescription drug costs
2016, Business, Issue 09-26-2016, Issues, Leading Headlines, News, Retail News
NEW YORK — With the 2016 presidential election drawing near, health care has emerged as a policy area in which the two major candidates’ differences are strikingly clear. A useful starting point might be their respective approaches to prescription drug pricing. The Republican candidate, Donald Trump, created a sensation in January when he advocated allowing
May 20, 2016 by Chain Drug Review
Chip Davis, EAR, Expedited Agency Review, FDA, Food and Drug Administration, generic drug labeling, generic drug manufacturers, generic drugs, Generic Pharmaceutical Association, GPhA
Featured Articles, Leading Headlines, Pharmacy, Supplier News
WASHINGTON — The Food and Drug Administration is again postponing the release of a final rule that would change generic drug labeling requirements. In a Federal Register notice this week, the FDA indicated that it aims to implement the final rule in April 2017, though many industry stakeholders had expected the agency to do so
May 19, 2016 by John Schultz and Chain Drug Review
FDA’s Office of Generic Drugs, Food and Drug Administration, generic drug approval process, generic drugs, Kathleen Uhl
Featured Articles, Leading Headlines, Pharmacy, Supplier News
WASHINGTON — Amid calls for a quicker approval process, the Food and Drug Administration last year cleared for market the most generic drug products in its history. The FDA said it approved or issued tentative approvals for more than 700 generic drugs in 2015. The announcement may help to blunt criticism from some federal legislators
February 24, 2016 by Chain Drug Review
Erez Vigodman, generic drugs, Iris Beck Codner, specialty medicines, Teva Pharmaceutical Industries
Supplier News
JERUSALEM, Israel — Teva Pharmaceutical Industries Ltd. has begun an enterprisewide corporate identity program to build a global brand. Teva said Wednesday that it will introduce and implement the new brand within the company over the next 12 months. The company noted that it plans to unveil the brand to its 43,000 employees worldwide before
February 23, 2016 by Chain Drug Review
Apotex, Chip Davis, generic drugs, Generic Pharmaceutical Association, GPhA, GPhA’s 2016 board of directors, Heather Bresch, Jeff Watson, mylan, Par Pharmaceuticals, Tony Pera
Pharmacy, Supplier News
ORLANDO, Fla. — The Generic Pharmaceutical Association (GPhA) has elected Heather Bresch, chief executive officer of Mylan, to chair its board of directors this year. GPhA, which announced the move at its 2016 Annual Meeting here, also named other officers to its 2016 board and executive committee: Jeff Watson, president of global generics at Apotex,
December 7, 2015 by Geoff Walden and Chain Drug Review
chain drug stores, generic drugs, Harris Poll, over-the-counter drugs, prescription drugs
2015, Issue 12-07-2015, Issues, News
NEW YORK — Americans prefer generic drugs to brands for both prescription and over-the-counter drugs, according to a new Harris Poll. Among those who purchase prescription drugs for themselves, nearly seven in 10 (69%) say, given a choice, they would opt for generics more often. Three in 10 go as far as saying they would
November 4, 2015 by Chain Drug Review
Chip Davis, generic drugs, Generic Pharmaceutical Association, GPhA
Featured Articles, Leading Headlines, Pharmacy, Supplier News
WASHINGTON — The U.S. health care system saved a record $254 billion last year through the use of lower-cost generic drugs, the Generic Pharmaceutical Association (GPhA) reports. Over the past decade, covering 2005 to 2014, the savings yielded by the use of generics over their more expensive brand-name counterparts totals $1.68 trillion, according to the
September 22, 2015 by Chain Drug Review
AmerisourceBergen, Cardinal Health, Celesio, CVS Health, drug channel, drug wholesalers, Fitch Ratings, generic drugs, McKesson, UDG Healthcare, Walgreens Boots Alliance
CDR Blog
McKesson’s deal to buy Ireland’s UDG Healthcare reflects the global consolidation of health care distribution, as drug wholesalers continue their drive for scale, especially in the realm of generic drugs, according to Fitch Ratings. “The UDG deal will add to McKesson’s generic purchasing power and further enhance its European pharmaceutical distribution presence, following its acquisition